Healthcare

• CSL will make an initial payment of US$355 million, with Alentis eligible for up to an additional US$1.2 billion in commercial milestones.

• A group proceeding has been filed in the Supreme Court of Victoria alleging CSL breached continuous disclosure obligations between February 2025 and May 2026

• The SECuRE trial's 8 GBq dose cohort showed 63% of evaluable participants achieving PSA50 reductions, with a favourable safety profile

• The global ACTH market is estimated at US$1.3 billion annually, representing a significant commercial opportunity for Clinuvel's second product

• The company completed its four-year, A$360 million distribution centre renewal program during the year

• H1 FY27 revenue is expected to reach approximately A$1.24 billion, representing around 14% year-over-year growth.

• Health NZ intends to use the land for a future hospitalFacilityto serve South Auckland's growing population.